Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 230

1.

Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Jensen MA, Thielen A, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

J Infect Dis. 2011 Jan 15;203(2):237-45. doi: 10.1093/infdis/jiq030.

PMID:
21288824
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.

Kagan RM, Johnson EP, Siaw M, Biswas P, Chapman DS, Su Z, Platt JL, Pesano RL.

PLoS One. 2012;7(9):e46334. doi: 10.1371/journal.pone.0046334. Epub 2012 Sep 27.

PMID:
23029482
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.

McGovern RA, Thielen A, Mo T, Dong W, Woods CK, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

AIDS. 2010 Oct 23;24(16):2517-25. doi: 10.1097/QAD.0b013e32833e6cfb.

PMID:
20736814
[PubMed - indexed for MEDLINE]
4.

Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078.

Portsmouth S, Valluri SR, Däumer M, Thiele B, Valdez H, Lewis M, Craig C, Thielen A, James I, Demarest J, Heera J.

Antiviral Res. 2013 Jan;97(1):60-5. doi: 10.1016/j.antiviral.2012.11.002. Epub 2012 Nov 16.

PMID:
23165088
[PubMed - indexed for MEDLINE]
5.

Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Thielen A, Jensen MA, Knapp DJ, Chapman D, Portsmouth S, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

Clin Infect Dis. 2011 Oct;53(7):732-42. doi: 10.1093/cid/cir493.

PMID:
21890778
[PubMed - indexed for MEDLINE]
Free Article
6.

Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.

Weber J, Vazquez AC, Winner D, Gibson RM, Rhea AM, Rose JD, Wylie D, Henry K, Wright A, King K, Archer J, Poveda E, Soriano V, Robertson DL, Olivo PD, Arts EJ, Quiñones-Mateu ME.

J Clin Microbiol. 2013 May;51(5):1517-27. doi: 10.1128/JCM.00092-13. Epub 2013 Mar 13.

PMID:
23486708
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.

McGovern RA, Symons J, Poon AF, Harrigan PR, van Lelyveld SF, Hoepelman AI, van Ham PM, Dong W, Wensing AM, Nijhuis M.

J Antimicrob Chemother. 2013 Sep;68(9):2007-14. doi: 10.1093/jac/dkt153. Epub 2013 May 14.

PMID:
23677920
[PubMed - indexed for MEDLINE]
Free Article
8.

HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.

Svicher V, Balestra E, Cento V, Sarmati L, Dori L, Vandenbroucke I, D'Arrigo R, Buonomini AR, Van Marck H, Surdo M, Saccomandi P, Mostmans W, Aerssens J, Aquaro S, Stuyver LJ, Andreoni M, Ceccherini-Silberstein F, Perno CF.

Antiviral Res. 2011 Apr;90(1):42-53. doi: 10.1016/j.antiviral.2011.02.005. Epub 2011 Feb 22.

PMID:
21349294
[PubMed - indexed for MEDLINE]
9.

Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.

McGovern RA, Thielen A, Portsmouth S, Mo T, Dong W, Woods CK, Zhong X, Brumme CJ, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):279-86. doi: 10.1097/QAI.0b013e31826249cf.

PMID:
23095934
[PubMed - indexed for MEDLINE]
10.

Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.

Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B; ANRS AC11 Resistance Study Group.

Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40. doi: 10.1128/AAC.00148-10. Epub 2010 Jun 7.

PMID:
20530226
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.

Swenson LC, Dong WW, Mo T, Demarest J, Chapman D, Ellery S, Heera J, Valdez H, Poon AF, Harrigan PR.

Clin Infect Dis. 2013 Jun;56(11):1659-66. doi: 10.1093/cid/cit105. Epub 2013 Feb 21.

PMID:
23429552
[PubMed - indexed for MEDLINE]
Free Article
12.

Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.

Baroncelli S, Galluzzo CM, Weimer LE, Pirillo MF, Volpe A, Mercuri A, Cavalli A, Fragola V, Monno L, Degli Antoni A, Ladisa N, Francisci D, Bucciardini R, Floridia M.

J Antimicrob Chemother. 2012 Jun;67(6):1479-85. doi: 10.1093/jac/dks055. Epub 2012 Feb 23.

PMID:
22361986
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.

Bon I, Clò A, Borderi M, Colangeli V, Calza L, Morini S, Miserocchi A, Cricca M, Gibellini D, Re MC.

Int J Infect Dis. 2013 Oct;17(10):e875-82. doi: 10.1016/j.ijid.2013.02.020. Epub 2013 Apr 15.

PMID:
23597487
[PubMed - indexed for MEDLINE]
Free Article
14.

[Methods for determination of HIV tropism and their clinical use].

Gutiérrez F, Rodríguez JC, García F, Poveda E.

Enferm Infecc Microbiol Clin. 2011 Dec;29 Suppl 5:45-50. doi: 10.1016/S0213-005X(11)70043-X. Review. Spanish.

PMID:
22305669
[PubMed - indexed for MEDLINE]
15.

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.

Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K, Moutschen M, Mostmans W, Kabeya K, Mackie N, Plum J, Vaira D, Van Baelen K, Vandenbroucke I, Van Eygen V, Van Marck H, Vogelaers D, Geretti AM, Stuyver LJ.

J Antimicrob Chemother. 2011 Feb;66(2):265-72. doi: 10.1093/jac/dkq458. Epub 2010 Dec 31.

PMID:
21196489
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H.

J Infect Dis. 2010 Mar 15;201(6):803-13. doi: 10.1086/650697.

PMID:
20151839
[PubMed - indexed for MEDLINE]
Free Article
17.

Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.

Seclén E, González Mdel M, Lapaz M, Rodríguez C, del Romero J, Aguilera A, de Mendoza C, Soriano V, Poveda E.

J Antimicrob Chemother. 2010 Dec;65(12):2502-4. doi: 10.1093/jac/dkq381. Epub 2010 Oct 12.

PMID:
20940179
[PubMed - indexed for MEDLINE]
Free Article
18.

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.

Symons J, van Lelyveld SF, Hoepelman AI, van Ham PM, de Jong D, Wensing AM, Nijhuis M.

J Antimicrob Chemother. 2011 Apr;66(4):890-5. doi: 10.1093/jac/dkq535. Epub 2011 Jan 28.

PMID:
21393136
[PubMed - indexed for MEDLINE]
Free Article
19.

Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism.

Archer J, Weber J, Henry K, Winner D, Gibson R, Lee L, Paxinos E, Arts EJ, Robertson DL, Mimms L, Quiñones-Mateu ME.

PLoS One. 2012;7(11):e49602. doi: 10.1371/journal.pone.0049602. Epub 2012 Nov 14.

PMID:
23166726
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.

Gonzalez-Serna A, McGovern RA, Harrigan PR, Vidal F, Poon AF, Ferrando-Martinez S, Abad MA, Genebat M, Leal M, Ruiz-Mateos E.

Antimicrob Agents Chemother. 2012 Mar;56(3):1202-7. doi: 10.1128/AAC.05857-11. Epub 2011 Dec 5.

PMID:
22143533
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk